Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OFIX
OFIX logo

OFIX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
12.035
Open
11.750
VWAP
11.72
Vol
527.09K
Mkt Cap
473.74M
Low
11.410
Amount
6.18M
EV/EBITDA(TTM)
12.17
Total Shares
40.42M
EV
581.79M
EV/OCF(TTM)
17.05
P/S(TTM)
0.56
Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.
Show More

Events Timeline

(ET)
2026-07-06
09:00:00
Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound
select
2026-07-06
08:00:00
Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels
select
2026-05-21 (ET)
2026-05-21
10:00:00
Orthofix Cuts FY Revenue Guidance, Shares Down 19.6% to $9.77
select
2026-05-21
10:00:00
Stock Down $2.38 to $9.77 in Morning Trading
select
2026-05-21
10:00:00
Orthofix Updates 2026 Financial Outlook, Expects Net Sales of $838M to $848M
select

News

seekingalpha
9.5
07-06seekingalpha
PinnedOrthofix Medical Stock Rises 16% Following CMS Reversal on Bone Growth Stimulators
  • Stock Surge: Orthofix Medical (OFIX) shares rose 16% on Monday, primarily driven by CMS's July 1 decision to reverse the final reclassification of non-invasive bone growth stimulators, which is expected to restore prior reimbursement levels and improve the company's financial outlook.
  • Analyst Insights: TD Cowen's analyst Matthew Blackman maintains a hold rating on OFIX, noting that CMS's decision allows the company to potentially return to previous reimbursement rates, thereby boosting market confidence in its future performance.
  • Market Reaction: Barrington's analyst Michael Petusky rates Orthofix as outperform, stating that the CMS reversal makes sense, although further assessment of reimbursement for bone growth stimulation products remains a possibility, which could impact the company's long-term strategy.
  • Future Outlook: While the stock price has surged due to CMS's decision, the market must remain vigilant regarding potential future changes in Medicare policies, which could have profound implications for Orthofix's business model and profitability.
NASDAQ.COM
9.5
07-07NASDAQ.COM
Innovative Eyewear Reports Significant Q2 Sales Growth
  • Significant Sales Growth: Innovative Eyewear Inc. (LUCY) announced preliminary Q2 2026 net sales of approximately $0.99 million, reflecting a 71% year-over-year increase, marking the twelfth consecutive quarter of revenue growth and demonstrating strong performance in the smart eyewear market.
  • Retail Partnership Expansion: The company secured an initial purchase order from a Canadian optical retail group operating 345 locations, with product deployment expected to begin in Q3 2026, which will further enhance its market penetration and brand influence.
  • Acquisition Proposal Raises Interest: Seer Inc. (SEER) received an unsolicited acquisition proposal from CEO Omid Farokhzad, offering $2.45 per share in cash, with the Board establishing a Special Committee to evaluate the proposal, potentially impacting the company's future strategic direction.
  • CMS Policy Reversal Benefits: Orthofix (OFIX) saw a 16% stock increase after CMS withdrew changes to reimbursement policies for non-invasive bone growth stimulators, which is expected to restore reimbursement rates to pre-May 18, 2026 levels, improving the company's financial outlook.
seekingalpha
9.5
07-02seekingalpha
Orthofix Medical Shares Rise 10% After CMS Withdraws Order on Bone Growth Stimulators
  • Stock Surge: Orthofix Medical's shares rose approximately 10% in after-hours trading on Thursday, primarily benefiting from CMS's withdrawal of a final order regarding non-invasive bone growth stimulators, which is expected to enhance the company's financial performance.
  • CMS Guidance Update: The revised guidance released by CMS on Wednesday indicates that the processing and payment for bone growth stimulators will align with treatment protocols in effect prior to the FDA reclassification, helping the company maintain existing billing requirements and Medicare fee schedules.
  • Market Impact: The decision to withdraw the order will prevent negative impacts on Orthofix's billing requirements, thereby safeguarding its revenue streams and potentially strengthening its competitive position in the medical device market.
  • Sales Outlook: Despite the Medicare changes, Orthofix reaffirmed its 2026 net sales outlook of $850 million to $860 million while targeting double-digit growth in U.S. limb reconstruction business in the second half of the year.
NASDAQ.COM
9.5
06-29NASDAQ.COM
Orthofix Shares Surge 5.1% Amid Strong Q1 Performance
  • Price Surge: Orthofix shares rose 5.1% to $9.78 in the last trading session, with trading volume significantly above average, reflecting investor optimism about the company's future performance.
  • Quarterly Results: In Q1 2026, Orthofix reported a loss of $0.52 per share with revenues of $196.7 million, showing a 3.1% year-over-year growth despite the loss, indicating some market demand.
  • Future Expectations: The upcoming quarter is expected to see a reduced loss of $0.03 per share, representing a year-over-year decline of 123.1%, suggesting cautious market sentiment regarding the company's future profitability, even as revenue expectations slightly increase.
  • Market Watch: Orthofix's consensus EPS estimate has remained unchanged over the past 30 days, indicating a potential lack of upward momentum in the stock price in the short term, prompting investors to closely monitor future earnings estimate revisions.
PRnewswire
7.0
06-05PRnewswire
Halper Sadeh LLC Investigates Orthofix Management for Fiduciary Breaches
  • Shareholder Rights Protection: Halper Sadeh LLC is investigating whether certain officers and directors of Orthofix Medical Inc. breached their fiduciary duties, allowing shareholders to consult on legal options at no cost to ensure their rights are protected.
  • Legal Fee Arrangement: The firm operates on a contingent fee basis, meaning shareholders do not have to bear upfront legal costs, thereby reducing the financial burden of participation in the investigation.
  • Opportunity for Governance Reform: Long-term shareholders of Orthofix may seek corporate governance reforms, fund recovery, or court-approved financial incentives, which could enhance the company's transparency and accountability.
  • Importance of Shareholder Participation: Active shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, successfully implementing corporate reforms.
PRnewswire
7.0
05-26PRnewswire
Purcell & Lefkowitz Investigates Orthofix Medical for Potential Fiduciary Breaches
  • Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Orthofix Medical Inc. to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
  • Shareholder Rights Protection: The investigation focuses on safeguarding the interests of Orthofix Medical's shareholders, ensuring they are informed about their rights and options, reflecting a strong emphasis on corporate governance.
  • Legal Consultation Services: Shareholders seeking more information can directly communicate with attorneys through the provided contact details, ensuring they receive professional legal advice at no cost or obligation.
  • Firm Background: Purcell & Lefkowitz LLP is dedicated to representing shareholders who are victims of securities fraud and breaches of fiduciary duty, demonstrating its commitment and expertise in protecting investor rights.
Wall Street analysts forecast OFIX stock price to rise
3 Analyst Rating
Wall Street analysts forecast OFIX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
18.00
Averages
21.33
High
24.00
Current: 0.000
sliders
Low
18.00
Averages
21.33
High
24.00
Barrington
Outperform
maintain
$15 -> $17
AI Analysis
2026-07-06
New
Reason
Barrington
Price Target
$15 -> $17
AI Analysis
2026-07-06
New
maintain
Outperform
Reason
Barrington raised the firm's price target on Orthofix to $17 from $15 and keeps an Outperform rating on the shares after the company disclosed via an 8-K filing on Friday that CMS had reversed itself on its very recent 10% reimbursement cut within traditional Medicare for non-invasive bone growth stimulators. As a result, the firm is reverting to the model it had built prior to May 18, the analyst tells investors.
Stifel
Buy -> Buy
downgrade
$22 -> $18
2026-03-09
Reason
Stifel
Price Target
$22 -> $18
2026-03-09
downgrade
Buy -> Buy
Reason
Stifel lowered the firm's price target on Orthofix to $18 from $22 and keeps a Buy rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OFIX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Orthofix Medical Inc (OFIX.O) is 500.00, compared to its 5-year average forward P/E of -4.85. For a more detailed relative valuation and DCF analysis to assess Orthofix Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.85
Current PE
500.00
Overvalued PE
120.67
Undervalued PE
-130.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.26
Current EV/EBITDA
7.56
Overvalued EV/EBITDA
12.01
Undervalued EV/EBITDA
6.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.84
Current PS
0.53
Overvalued PS
1.16
Undervalued PS
0.52

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks to swingmax trading for today
Intellectia · 65 candidates
Region: USRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CLRO logo
CLRO
Clearone Inc
18.73M
ZCMD logo
ZCMD
Zhongchao Inc
92.84K
LUCY logo
LUCY
Innovative Eyewear Inc
7.94M
WBX logo
WBX
Wallbox NV
96.40M
SBEV logo
SBEV
Splash Beverage Group Inc
3.36M
SEER logo
SEER
Seer Inc
120.41M
what to buy High risk
Intellectia · 12 candidates
Market Cap Category: small, midRsi Category: moderateRelative Vol: >= 1.80Beta: HighRiskMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00News Driver: Positive
Ticker
Name
Market Cap$
top bottom
CIFR logo
CIFR
Cipher Digital Inc
9.04B
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
TDC logo
TDC
Teradata Corp
2.84B
YOU logo
YOU
Clear Secure Inc
7.84B
AVTX logo
AVTX
Avalo Therapeutics Inc
434.38M
AZTA logo
AZTA
Azenta Inc
1.13B
day trading where do i go
Intellectia · 429 candidates
Price: $2.00 - $100.00Price Change Pct: >= $0.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CLRB logo
CLRB
Cellectar Biosciences Inc
12.00M
BLZE logo
BLZE
Backblaze Inc
278.47M
AURA logo
AURA
Aura Biosciences Inc
536.07M
CYTK logo
CYTK
Cytokinetics Inc
8.21B
VRDN logo
VRDN
Viridian Therapeutics Inc
1.45B
EVER logo
EVER
EverQuote Inc
516.80M
what are the best day trades for tommarow
Intellectia · 19 candidates
Region: USPrice: $10.00 - $80.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: 2.0% - 10.0%Monthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
ATKR logo
ATKR
Atkore Inc
2.22B
GGAL logo
GGAL
Grupo Financiero Galicia SA
7.64B
MMYT logo
MMYT
MakeMyTrip Ltd
4.03B
ACMR logo
ACMR
ACM Research Inc
3.03B
AEHR logo
AEHR
Aehr Test Systems
1.96B
GME logo
GME
GameStop Corp
10.27B

Whales Holding OFIX

A
Armistice Capital LLC
Holding
OFIX
+20.55%
3M Return
R
Rubric Capital Management LP
Holding
OFIX
+8.04%
3M Return
P
Paradigm Capital Management, Inc.
Holding
OFIX
+6.62%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Orthofix Medical Inc (OFIX) stock price today?

The current price of OFIX is 11.72 USD — it has increased 1.3

What is Orthofix Medical Inc (OFIX)'s business?

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

What is the price predicton of OFIX Stock?

Wall Street analysts forecast OFIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OFIX is21.33 USD with a low forecast of 18.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Orthofix Medical Inc (OFIX)'s revenue for the last quarter?

Orthofix Medical Inc revenue for the last quarter amounts to 196.71M USD, increased 1.58

What is Orthofix Medical Inc (OFIX)'s earnings per share (EPS) for the last quarter?

Orthofix Medical Inc. EPS for the last quarter amounts to -0.52 USD, decreased -61.48

How many employees does Orthofix Medical Inc (OFIX). have?

Orthofix Medical Inc (OFIX) has 1605 emplpoyees as of July 08 2026.

What is Orthofix Medical Inc (OFIX) market cap?

Today OFIX has the market capitalization of 473.74M USD.